Leap Therapeutics Inc. buy melinda
Start price
15.10.18
/
50%
€55.92
Target price
22.01.19
€66.75
Performance (%)
-46.77%
End price
22.01.19
€29.77
Summary
This prediction ended on 22.01.19 with a price of €29.77. The BUY prediction by melinda for Leap Therapeutics Inc. performed very badly with a performance of -46.77%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Leap Therapeutics Inc. | -50.959% | -50.959% | 36.905% | -94.065% |
| iShares Core DAX® | -1,86 % | 0,67 % | 0,92 % | 51,85 % |
| iShares Nasdaq 100 | -3,32 % | 4,99 % | 33,72 % | 86,85 % |
| iShares Nikkei 225® | -2,30 % | 6,13 % | 52,96 % | 63,32 % |
| iShares S&P 500 | -1,31 % | 3,40 % | 24,67 % | 66,11 % |
Comments by melinda for this prediction
In the thread Leap Therapeutics Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
Engages in clinical stage immuno-oncology
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company.
It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics.
The firm's pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.
The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company.
It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics.
The firm's pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.
The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Nombre d'employés : 22 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Leap Therapeutics Inc.
Leap Therapeutics Inc.
Start price
Target price
Perf. (%)
€16.40
27.09.20
27.09.20
€20.00
04.11.21
04.11.21
38.72%
05.11.21
05.11.21
Leap Therapeutics Inc.
Start price
Target price
Perf. (%)
€67.56
25.04.17
25.04.17
€70.81
05.05.17
05.05.17
5.74%
05.05.17
05.05.17